A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis.
John O MascarenhasAnna Rita MigliaccioHeidi E KosiorekRupali BhaveJeanne M PalmerAndrew T KuykendallRuben A MesaRaajit K RampalAaron T GerdsAbdulraheem YacoubKristen PettitMoshe TalpazRami S KomrokjiMarina KremyanskayaAgapito GonzalezFrank FabrisKathryn JohnsonMikaela DoughertyErin M McGovernJuan Esteban Arango OssaDylan DomenicoNoushin FarnoudRona Singer WeinbergAmy KongVesna NajfeldAlessandro Maria Maria VannucchiFrancesca ArcipreteMaria ZingarielloMario FalchiMohamed E SalamaCarolyn Mead-HarveyAmylou C DueckLilian VarricchioRonald HoffmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
AVID200 is a well-tolerated, rational, therapeutic agent for the treatment of MF patients and should be evaluated further in thrombocytopenic MF patients in combination with agents that target aberrant MF intracellular signaling pathways.